{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pandemic+Influenza+Immunization",
    "query": {
      "condition": "Pandemic Influenza Immunization"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 9,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T06:49:42.205Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06727058",
      "title": "Study to Evaluate Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza Immunization"
      ],
      "interventions": [
        {
          "name": "Pandemic flu H5 mRNA vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 276,
      "start_date": "2024-12-09",
      "completion_date": "2026-03-24",
      "has_results": false,
      "last_update_posted_date": "2026-04-23",
      "last_synced_at": "2026-07-24T06:49:42.205Z",
      "location_count": 14,
      "location_summary": "La Mesa, California • DeLand, Florida • Lakeland, Florida + 11 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06727058"
    },
    {
      "nct_id": "NCT00310206",
      "title": "H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Inactivated Influenza A Vaccine A/H5N1",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 100,
      "start_date": "2005-07",
      "completion_date": "2006-10",
      "has_results": false,
      "last_update_posted_date": "2013-06-03",
      "last_synced_at": "2026-07-24T06:49:42.205Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00310206"
    },
    {
      "nct_id": "NCT01059617",
      "title": "Safety and Immune Response of Candidate H1N1 Influenza Vaccine GSK2340274A Following Seasonal Influenza Vaccination in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "GSK Biologicals' FluLaval®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo (saline)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "GlaxoSmithKline",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "19 Years to 40 Years"
      },
      "enrollment_count": 133,
      "start_date": "2010-02-09",
      "completion_date": "2011-10-21",
      "has_results": true,
      "last_update_posted_date": "2018-08-20",
      "last_synced_at": "2026-07-24T06:49:42.205Z",
      "location_count": 3,
      "location_summary": "Milford, Massachusetts • Salisbury, North Carolina • Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Milford",
          "state": "Massachusetts"
        },
        {
          "city": "Salisbury",
          "state": "North Carolina"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01059617"
    },
    {
      "nct_id": "NCT05874713",
      "title": "Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human",
        "Infections",
        "Respiratory Tract Infections",
        "Virus Diseases",
        "Infection Viral"
      ],
      "interventions": [
        {
          "name": "aH5N8c on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aH5N6c on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aH5N8c on Day 22",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aH5N6c on Day 22",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aH5N8c on Day 202",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 480,
      "start_date": "2023-06-07",
      "completion_date": "2024-09-25",
      "has_results": false,
      "last_update_posted_date": "2024-12-13",
      "last_synced_at": "2026-07-24T06:49:42.205Z",
      "location_count": 9,
      "location_summary": "Cullman, Alabama • Lilburn, Georgia • Norcross, Georgia + 6 more",
      "locations": [
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Lilburn",
          "state": "Georgia"
        },
        {
          "city": "Norcross",
          "state": "Georgia"
        },
        {
          "city": "Sioux City",
          "state": "Iowa"
        },
        {
          "city": "Baton Rouge",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05874713"
    },
    {
      "nct_id": "NCT02251288",
      "title": "A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Avian Influenza",
        "Immunisation"
      ],
      "interventions": [
        {
          "name": "Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MF59 adjuvant",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "47 Years",
        "sex": "ALL",
        "summary": "18 Years to 47 Years"
      },
      "enrollment_count": 62,
      "start_date": "2015-05-18",
      "completion_date": "2018-08-17",
      "has_results": false,
      "last_update_posted_date": "2020-01-27",
      "last_synced_at": "2026-07-24T06:49:42.205Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02251288"
    },
    {
      "nct_id": "NCT05422326",
      "title": "A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza, Human",
        "Influenza in Birds",
        "Respiratory Tract Infections",
        "Infections",
        "Orthomyxoviridae Infections",
        "RNA Virus Infections",
        "Virus Diseases",
        "Respiratory Tract Diseases"
      ],
      "interventions": [
        {
          "name": "aH5N6c on Day 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "aH5N6c on Day 22",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo on Day 22",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 260,
      "start_date": "2022-07-18",
      "completion_date": "2023-03-24",
      "has_results": true,
      "last_update_posted_date": "2026-05-13",
      "last_synced_at": "2026-07-24T06:49:42.205Z",
      "location_count": 18,
      "location_summary": "Huntsville, Alabama • Tempe, Arizona • San Diego, California + 14 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Milford",
          "state": "Connecticut"
        },
        {
          "city": "Clearwater",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05422326"
    },
    {
      "nct_id": "NCT06907511",
      "title": "Study to Evaluate the Safety and the Immunogenicity of a Second Generation Structurally Designed mRNA Vaccine Candidate Against Pandemic Influenza H5 HA Strain in Healthy Adult Participants Aged 18 Years and Older",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Pandemic Influenza Immunization",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Pandemic flu H5 HA mRNA SD2 vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 720,
      "start_date": "2025-04-17",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-01-16",
      "last_synced_at": "2026-07-24T06:49:42.205Z",
      "location_count": 13,
      "location_summary": "La Mesa, California • DeLand, Florida • Lakeland, Florida + 10 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Lakeland",
          "state": "Florida"
        },
        {
          "city": "Largo",
          "state": "Florida"
        },
        {
          "city": "Decatur",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06907511"
    },
    {
      "nct_id": "NCT04794829",
      "title": "Natural History of Systemic and Nasal Mucosal Immunity to Influenza and SARS-CoV-2 in Adults After Vaccination",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Influenza",
        "COVID-19"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 150,
      "start_date": "2021-08-19",
      "completion_date": "2026-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-08",
      "last_synced_at": "2026-07-24T06:49:42.205Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04794829"
    },
    {
      "nct_id": "NCT00812019",
      "title": "Dose Ranging Study to Evaluate Immunogenicity and Safety of Adjuvanted or Non-adjuvanted Cell Culture-derived H5N1 Influenza Vaccine in Young Adults (18-40 Years Old)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Seqirus",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "18 Years to 40 Years"
      },
      "enrollment_count": 753,
      "start_date": "2008-11",
      "completion_date": "2010-11",
      "has_results": false,
      "last_update_posted_date": "2020-08-24",
      "last_synced_at": "2026-07-24T06:49:42.205Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00812019"
    }
  ]
}